Last updated: May 31, 2026
XELSTRYM suppliers: who manufactures, sources, and fills the d-amphetamine prodrug for the US market
Xelstrym (dextroamphetamine sulfate extended-release prodrug/“prodrug” amphetamine system, FDA-approved for ADHD in certain pediatric and adult populations) is supplied through a vertically integrated chain that typically includes: (1) API or key intermediate sourcing, (2) drug-product manufacturing and film-coating/controlled release processing, (3) sterile or non-sterile packaging line operations, and (4) labeling and distribution under FDA and state licensing.
However, no supplier-identifying details (site-level drug-product manufacturing, API manufacturers, or contract partners) are provided in the information available here. Without those specifics, any list of “suppliers” would be incomplete or potentially incorrect.
What companies supply Xelstrym (FDA drug product) and who are its contract manufacturers?
Answer: Not available from the provided dataset.
What roles exist in the Xelstrym supply chain
- API / key intermediate manufacture
- Drug-product manufacturing (controlled release prodrug system assembly)
- Film coating / granulation / extrusion-spheronization or equivalent controlled-release steps
- Batch release testing (quality control and stability)
- Packaging and labeling (bottling/blistering, carton and NDC labeling)
- Distribution and wholesaler fulfillment
Which Xelstrym sites manufacture the drug product (NDA labeling, facility names)?
Answer: Not available from the provided dataset.
How site identification usually appears
- Label section listing “Manufactured for” or “Distributed by”
- FDA label (highlights and full prescribing information)
- Drug master file references linked to labeling manufacturing statement
- State licensing and inspection records (when available)
Who supplies Xelstrym API or key intermediates (dextroamphetamine-related raw materials)?
Answer: Not available from the provided dataset.
Typical API sourcing disclosures that would be required
- API manufacturer name and facility in DMF/labeling cross-references
- Commercial intermediate supplier in controlled-release formulation dossiers
- Evidence from batch records or GMP certificates tied to release
What is the Orange Book status of Xelstrym and does it list manufacturing partners?
Answer: Not available from the provided dataset.
What Orange Book listings normally tell you
- NDA holder
- Active ingredient
- Dosage form and route
- Patents and exclusivity (not supplier names per se)
When does Xelstrym lose exclusivity and will supplier switching occur before generic entry?
Answer: Not available from the provided dataset.
What drives supplier switching
- Route to market changes after exclusivity ends
- Procurement shifts to alternate controlled-release manufacturing platforms
- Contract renegotiation based on volume and regulatory inspection outcomes
What generic entry risks exist for Xelstrym and how does that affect supplier concentration?
Answer: Not available from the provided dataset.
Key risk areas that would matter
- Complexity of controlled-release prodrug design
- Patent estate strength around formulation and method of use
- Scale-up and process validation barriers
How does Xelstrym compare to other amphetamine ADHD prodrugs on manufacturing complexity and supply risk?
Answer: Not available from the provided dataset.
What comparison would require
- Controlled-release platform type
- Comparable NDA holders and contract manufacturer ecosystems
- Similarity in formulation constraints and rate-controlling steps
Key Takeaways
- Supplier identification for Xelstrym (drug-product manufacturers, API suppliers, and contract manufacturing partners) cannot be established from the information provided here.
- Patent and Orange Book status, which often informs competitive and supply timing strategies, also cannot be confirmed from the provided dataset.
FAQs
- Does Xelstrym use a contract manufacturing organization (CMO) or is it made by the NDA holder’s own plants?
- Are Xelstrym drug products manufactured in the US or abroad, and which GMP sites are listed on the label?
- Which company holds the FDA NDA for Xelstrym and who is listed as “manufactured for” on the package insert?
- Do DMFs for Xelstrym disclose API or intermediate manufacturers that can be treated as suppliers?
- Will supplier concentration change as Xelstrym approaches loss of exclusivity and generic launches?
References
(No sources were provided in the prompt content.)
